Dynamics of changes in the level of IgA in patients with bronchial asthma against the background of excessive body weight or obesity
DOI:
https://doi.org/10.15584/ejcem.2019.3.1Keywords:
bronchial asthma, excessive body weight, obesityAbstract
Introduction. Among patients with asthma, a lot of attention is being given to, at the present time, to such comorbidity as excessive body mass (EBM) or obesity.
Aim. To evaluate the level of IgA in patients with bronchial asthma against the background of excessive body weight or obesity and to evaluate the effects of drug on the bacterial lysate and inosine pranobex.
Material and methods. According to the design, the study was conducted in two stages: the first stage – examination of 105 patients with asthma. 105 patients with a basic diagnosis of asthma were examined whose average age was 41.19 ± 1.05 years, 75 patients were found to have EBM or obesity (BMI 31.67 ± 0.53) who were included in the main group and 30 patients with NBMI (BMI 22.13 ± 0.32), which were the comparison group.
Results. The patients in the main group with a severe course had significantly lower serum IgA values than the patients in the comparison group (p<0.05), but the statistically significant difference between this index in the patients with a severe course in the main group and the control group was not revealed. The patients in the main group had a significant increase in the level of secret IgA against the background of the use of treatment-and-prophylactic complex (TPC) with the inclusion of a preparation of bacterial lysate in combination with inosine pranobex against the background of training in asthma school, receiving the basic treatment (p<0.05).
Conclusion. Patients with asthma who have large BMI have a more severe course of bronchial asthma. A Correlation relationship was established in the group of patients with bronchial asthma and with excessive body weight or obesity between the level of sIgA and the severity of the asthma course; there is a direct strong correlation. Patients in the main group had a significant increase in the level of sIgA against the background of the use of TPC with the addition of a basic treatment by the preparation of bacterial lysate together with inosine pranobex.
Downloads
References
Loo SL, Wark PA. Recent advances in the understanding and managing asthma. F1000Res. 2016;5. doi: 10.12688/f1000research.9236.1.
Marko M, Pawliczak R. Obesity and Asthma: Risk, Control and Treatment. Postepy Dermatol Alergol. 2018;35(6):563-571.
Ford ES, Mannino DM. Time trends in obesity among adults with asthma in the United States: findings from three national surveys. J Asthma Off J Assoc Care Asthma. 2005;42:91-95.
Akerman MJ, Calacanis CM, Madsen MK. Relationship between asthma severity and obesity. J Asthma Off J Assoc Care Asthma. 2004;41:521-526.
Pradeepan S, Garrison G, Dixon AE. Obesity in asthma: approaches to treatment. Curr Allergy Asthma Rep. 2013;13:434-442.
Immunoglobulin A serum. https://spravochnik.synevo.ua/ru/immunnaia-sistema/immunoglobulin-a.html. Assessed 05 July 2019.
Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol. 2018;53(6):691-700.
Ivanov VD, Makovetskaya AK. Possibilities of using noninvasive immunological methods in the assessment of public health. Noninvasive methods in assessing the health of the population. Rakhmaninov YuA, еditor. M; 2006:112-125.
WhiteMA, Diffenbaugh NS, Jones GV, Pal JS, Giorgi F. Extreme Heat reduces and shifts United States premium wine production in the 21st century. Proc Natl Acad Sci USA. 2006;103(30):11217-11222.
Woof JM, Russell MW. Structure and functional relationships in IgA. Mucosal Immunol. 2011;4(6):590-597.
Kim WJ, Choi IS, Kim CS, Lee JH, Kang HW. Relationship between serum IgA level and allergy/asthma. Korean J Intern Med. 2017;32(1):137-145.
Fagerås M, Tomičić S, Voor T, Björkstén B, Jenmalm MC. Slow salivary secretion IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children. Pediatric research. 2011;70(6):572-577.
Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. Immune Evasion by Epstein-Barr Virus. Curr Top Microbiol Immunol. 2015;391:355-81.
Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012;25(1):62-68.
Pavlova KS, Kurbacheva OM. A difficult patient - a patient with frequent relapsing diseases of the respiratory tract. Pharmacy. 2015;6(299):46-49.
De Benedetto F, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchommunal in children and adults: a state of the art. Multidiscip Respir Med. 2013;8(1):33. doi: 10.1186/2049-6958-8-33
Karaca NE, Gulez N, Aksu G, Azarsiz E, Kutukculer N. Does OM-85 BV prophylaxis trigger autoimmunity in IgA deficient children? Int Immunopharmacol. 2011;11:1747-1751.
Gołebiowska-Wawrzyniak M, Markiewicz K, Kozar A, et al. Immunological and clinical study on therapeutic efficacy of inosine pranobex. Pol Merkur Lekarski. 2005;19(111):379-382.
Osidak LV, Zarubaev VV, Obrazcova EV, et al. Isoprinosis in the treatment of acute respiratory viral infections in frequently sick children. Infant infections. 2008;4:35-41.
Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151(1):42-50.
Esposito S, Soto-Martinez M, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18(3):198-209.
Bulgakova VA, Balabolkin II, Sedova MS, et al. Clinical and immunological efficacy of pronobex inosine in acute respiratory infections in children with atopic bronchial asthma. Pediatric pharmacology. 2010;7(3):98-105.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
